Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-67953964 Gastric Safety Study
NCT04185051Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2019
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of aticaprant in major depressive disorder (MDD) (2 cohorts), sponsored by Janssen Pharmaceutical. Primary endpoint: Percentage of Participants with Microscopic Signs of Parietal Cell Damage at Day 28. Started Dec 2019; status: completed.
02
Drugs
aticaprant
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04185051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04185051.